title: [Ebola and Marburg viruses: the humans strike back].
abstract: Ebola and Marburg viruses are the causative agents of rapidly progressive hemorrhagic fevers with high mortality rates. Pre- or post-exposure treatments against the diseases are currently not available for human use. In the field, establishment of strict quarantine measures preventing further virus transmission are still the only way to fight the infections. However, our knowledge of Ebola and Marburg viruses has markedly increased as a result of two recent discoveries discussed in this review. Chandran et al. have elucidated the mechanism by which Ebola GP is converted to a fusion-active form. Infectivity of Ebola virus was shown to be dependent on the cleavage of GP by cellular endosomal proteases, cathepsin B and L, thus opening new therapeutic approaches options. As for Jones SM et al., they have successfully vaccinated monkeys with recombinant vesicular stomatitis virus expressing Ebola or Marburg virus surface glycoprotein GP, a promising vaccine approach.
authors.affiliation: Laboratoire des Filovirus, Inserm U758, ENS Lyon, IFR 128 BioSciences Lyon-Gerland, Université Claude Bernard Lyon 1, France.
authors.forename: Nathalie
authors.initials: N
authors.lastname: Alazard-Dany
authors.forename: Michèle
authors.initials: M
authors.lastname: Ottmann Terrangle
authors.forename: Viktor
authors.initials: V
authors.lastname: Volchkov
mesh_terms: D000350:Africa, Central / Q000453:epidemiology; D000818:Animals; D002401:Cathepsin B / Q000502:physiology; D056668:Cathepsin L; D002403:Cathepsins / Q000502:physiology; D003264:Containment of Biohazards; D003546:Cysteine Endopeptidases / Q000502:physiology; D004196:Disease Outbreaks; D046129:Ebola Vaccines / Q000276:immunology; D029043:Ebolavirus / Q000235:genetics / Q000276:immunology / Q000502:physiology; D011992:Endosomes / Q000201:enzymology / Q000821:virology; D016679:Genome, Viral; D006168:Guinea Pigs; D019142:Hemorrhagic Fever, Ebola / Q000453:epidemiology / Q000517:prevention & control* / Q000635:transmission / Q000821:virology; D006801:Humans; D008379:Marburg Virus Disease / Q000453:epidemiology / Q000517:prevention & control* / Q000635:transmission / Q000821:virology; D029024:Marburgvirus / Q000235:genetics / Q000276:immunology / Q000502:physiology; D008561:Membrane Fusion; D051379:Mice; D011323:Primates; D011790:Quarantine; D014614:Vaccines, Synthetic / Q000276:immunology; D014721:Vesicular stomatitis Indiana virus / Q000276:immunology; D014759:Viral Envelope Proteins / Q000276:immunology; D014765:Viral Vaccines / Q000276:immunology
chemical_list: D046129:Ebola Vaccines; D014614:Vaccines, Synthetic; D014759:Viral Envelope Proteins; D014765:Viral Vaccines; C113189:envelope glycoprotein, Ebola virus; D002403:Cathepsins; D003546:Cysteine Endopeptidases; D002401:Cathepsin B; C534281:CTSL protein, human; D056668:Cathepsin L; C534278:Ctsl protein, mouse